These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12146462)

  • 1. The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society.
    Havlir D; Vella S; Hammer S
    AIDS; 2002 Jul; 16(10):7-9. PubMed ID: 12146462
    [No Abstract]   [Full Text] [Related]  

  • 2. Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USA.
    Hicks CB
    AIDS Clin Care; 2008 Aug; 20(8):64. PubMed ID: 18814369
    [No Abstract]   [Full Text] [Related]  

  • 3. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.
    Kouanfack C; Montavon C; Laurent C; Aghokeng A; Kenfack A; Bourgeois A; Koulla-Shiro S; Mpoudi-Ngole E; Peeters M; Delaporte E
    Clin Infect Dis; 2009 May; 48(9):1318-22. PubMed ID: 19320592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
    Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
    Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.
    Bertagnolio S; Derdelinckx I; Parker M; Fitzgibbon J; Fleury H; Peeters M; Schuurman R; Pillay D; Morris L; Tanuri A; Gershy-Damet GM; Nkengasong J; Gilks CF; Sutherland D; Sandstrom P
    Antivir Ther; 2008; 13 Suppl 2():49-57. PubMed ID: 18575191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
    Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
    Hirsch MS; Brun-Vézinet F; Clotet B; Conway B; Kuritzkes DR; D'Aquila RT; Demeter LM; Hammer SM; Johnson VA; Loveday C; Mellors JW; Richman DD;
    Top HIV Med; 2003; 11(4):150-4. PubMed ID: 12876334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update of the Drug Resistance Mutations in HIV-1: 2005.
    Johnson VA; Brun-Vezinet F; Clotet B; Conway B; Kuritzkes DR; Pillay D; Schapiro J; Telenti A; Richman D
    Top HIV Med; 2005; 13(1):51-7. PubMed ID: 15849371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow accumulation of HIV resistance mutations: implications for resource-limited settings?
    Stevens WS
    J Infect Dis; 2009 Sep; 200(5):670-2. PubMed ID: 19604045
    [No Abstract]   [Full Text] [Related]  

  • 11. Why HIV drug resistance matters: an overview.
    Learned J
    Posit Aware; 2005; 16(5):26-30. PubMed ID: 16220604
    [No Abstract]   [Full Text] [Related]  

  • 12. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 13. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.
    Bennett DE
    Curr Opin Infect Dis; 2006 Dec; 19(6):607-14. PubMed ID: 17075338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the drug resistance mutations in HIV-1: Fall 2005.
    Johnson VA; Brun-Vezinet F; Clotet B; Conway B; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2005; 13(4):125-31. PubMed ID: 16304457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV drug resistance and you. Resistance overview. A look at the basics.
    Munk B
    Posit Aware; 2006; Spec No():6-9. PubMed ID: 16583502
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV/AIDS in China. A new treatment campaign, but with limited weapons.
    Cohen J
    Science; 2004 Jun; 304(5676):1433. PubMed ID: 15178778
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiretroviral rounds. Resistance: how do you know if you don't know?
    Campbell TB; Katzenstein D
    AIDS Clin Care; 2005 Mar; 17(3):26-7. PubMed ID: 15828117
    [No Abstract]   [Full Text] [Related]  

  • 18. Accrued HIV evidence turns treatment dogma on its head.
    Check E
    Nature; 2003 Aug; 424(6951):866. PubMed ID: 12931150
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical data marshalled to treat HIV.
    Clarke T
    Nature; 2003 Jun; 423(6942):791. PubMed ID: 12815390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.